Stanley Laman Group Ltd. Makes New $5.23 Million Investment in Bruker Co. (NASDAQ:BRKR)

Stanley Laman Group Ltd. acquired a new position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 89,208 shares of the medical research company's stock, valued at approximately $5,229,000. Stanley Laman Group Ltd. owned about 0.06% of Bruker as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in BRKR. Wealth Enhancement Advisory Services LLC lifted its holdings in Bruker by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock valued at $779,000 after acquiring an additional 177 shares during the last quarter. UMB Bank n.a. raised its position in Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after purchasing an additional 248 shares during the period. Blue Trust Inc. lifted its stake in shares of Bruker by 13.5% in the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock valued at $127,000 after purchasing an additional 257 shares during the last quarter. US Bancorp DE grew its holdings in shares of Bruker by 2.1% during the 3rd quarter. US Bancorp DE now owns 12,700 shares of the medical research company's stock worth $877,000 after purchasing an additional 260 shares during the period. Finally, Coldstream Capital Management Inc. increased its position in shares of Bruker by 7.3% during the 3rd quarter. Coldstream Capital Management Inc. now owns 4,553 shares of the medical research company's stock worth $312,000 after purchasing an additional 308 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Stock Down 2.2 %

NASDAQ:BRKR traded down $1.11 during mid-day trading on Monday, hitting $50.04. The stock had a trading volume of 2,044,498 shares, compared to its average volume of 1,412,424. Bruker Co. has a twelve month low of $48.07 and a twelve month high of $94.86. The stock has a 50-day simple moving average of $57.56 and a two-hundred day simple moving average of $60.48. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $7.59 billion, a PE ratio of 24.06, a PEG ratio of 3.81 and a beta of 1.16.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 9.41% and a return on equity of 21.52%. On average, equities research analysts anticipate that Bruker Co. will post 2.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. UBS Group initiated coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 target price on the stock. TD Cowen decreased their price target on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research note on Wednesday, November 6th. Barclays dropped their price objective on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Citigroup lowered their target price on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group upgraded shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $70.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.